. Improved prodrug caging increases maximum nontoxic dose in cells. a) Chemical structures of parent doxorubicin and the prodrug caged with Alloc-or Alloc-SIL-C16 groups. b-c) Viability of HT1080 fibrosarcoma cells was measured following 72 h treatment with doxorubicin and its caged counterparts, shown as a dose-response (b) and quantified (c) according to the concentration yielding 50% reduced viability (IC50), in the presence or absence of 50 μM Pd-NP (n = 2, means ± s.e.m.). Figure S5 . Monitoring in vitro prodrug activation. a) HT1080 tumor cells were co-treated with C16proDOX and Pd-NP for 24 h, and then imaged by fluorescence microscopy to quantify subcellular drug accumulation based on endogenous fluorescence of anthracycline and Pd compound (scale bar 50 μm). b) Pixel-by-pixel co-localization was quantified by selecting ROI over perinuclear regions high in Pd signal based on images as in a (see yellow outlined regions in white dashed box for representative ROIs); for comparison, similar co-localization statistics were also computed for comparing PLGA-PEG NP vehicle (labeled with PLGA-BODIPY630) with a fluorescently-labeled, co-encapsulated C16 prodrug (C16-Pt(IV)-BODIPY; see [Miller et al., 2015, Nat Commun, 6, 8692] ). c-d) HPLC fluorescence detection was used to discriminate doxorubicin and C16proDOX based on elution time (c, 50 μM standards), from HT1080 cell lysates following treatment. Representative HPLC fluorimetry trace (d) and corresponding quantification (e; means ± s.d., n = 3) are shown based on peaks at the described elution times. f) Representative ELSD detection of C16proMMAE activation by PdNP after 24h. g) At red shading in f, LC-MS (ESI) calc for MMAE (C39H68N5O7 {M+H}+ 719.0, found 718.7) only detected with Pd-NP incubation (n=2). , the PLGA-PEG vehicle (labeled with PLGA-BODIPY630) of a model nano-encapsulated prodrug substrate (Alloc2R110) (middle column), and the Pd-mediated activation of that substrate (right column) are shown 24 h post-administration in animals bearing HT1080 tumors. Concentration was determined by ICP-MS (for Pd) and reflectance fluorescence microscopy (for prodrug vehicle and prodrug activation), and normalized to the concentration found in tumors (n = 3; see [Miller et al., 2017, Nat Commun, 8, 15906] ). Data corresponds to Fig. 6d . b-c) Individual tumor growth curves, corresponding to Figs. 5 and 7, are plotted alongside their mean (thick line) and s.e.m. (error bars) for the MC38 (b) and HT1080 (c) models. Red arrows denote the day of treatment. Representative tumor images show unaffected and blocked tumor growth at top and bottom, respectively, corresponding to their adjacent treatment groups (scale bar, 5 mm). d) The coefficient of variation (CV) in day 8 tumor volume measurements was calculated across both MC38 and HT1080 tumor models, including using single-treatment controls, solvent based formulation of doxorubicin, and a nanoformulated doxorubicin (see [Miller et al., 2017, Nat Commun, 8, 15906] for DOXNP and DOX treatments and descriptions; n ≥ 5 tumors; F-test to compare variances of the treatment group against their respective no-treatment control). e) Weights of animals bearing HT1080 tumors were measured following local low-dose radiation and combination Pd-NP prodrug-NP treatments (n ≥ 3; means ± s.e.m.). Gray and red arrows denote RT and NP treatments. Figure S8 . Pharmacokinetic model sensitivity analysis. Following parameter optimization, the pharmacokinetic model (see Fig. 6a ) was computed while adjusting parameter values by ± 10% (indicated along vertical axis). Change in simulation features 24 h following prodrug administration (horizontal axis) were quantified as a fraction of that feature's value. The ratio of fractional changes in feature values to fractional changes in parameter values (the parametric sensitivities) were then hierarchically clustered and plotted as a heatmap. "Long dose delay" describes changes observed when dose staggering is adjusted from 0 h (co-injection) to 24 h (but without changing the ratio denominator, Δ parameter, for comparison to "dose delay", which examines the impact of adjusting ± 10% around the 5 h dose staggering. The yellow box highlights the relative impacts of PtSt on NP accumulation and prodrug activation in the tumor. [Baxter et al., 1994 , Cancer Res, 54, 1517 Hendriks et al., 2012, CPT Pharmacometrics Syst Pharmacol, 1, e15] kel plasma elimination 0.01 ± 0.003 min -1 initialized from [Baxter et al., 1994 , Cancer Res, 54, 1517 PSCP plasma / heart interst. transport [1.2 ± 0.4] 10 -6 mL min -1 permeability * surface area Vh interstitial heart volume 0.019 mL [Baxter et al., 1994 , Cancer Res, 54, 1517 Vtot h total heart volume 0.133 mL [Baxter et al., 1994 , Cancer Res, 54, 1517 CLi plasma / liver convective transport 1.1 mL min -1 convective transport [Baxter et al., 1994 , Cancer Res, 54, 1517 
VLV
volume of liver vasculature 0.095 mL [Baxter et al., 1994 , Cancer Res, 54, 1517 Vtot L total liver volume 0.95 mL [Baxter et al., 1994 , Cancer Res, 54, 1517 kKu 2 nd -order Kup er cell uptake 0.016 ± 0.008 (mg/mL) -1 min -1 initialized from in vitro NP uptake data: [Miller et al., 2017, Sci Transl Med, 9, eaal0225] Pt permeability of tumor vasc. 3.1 ± 1 10 -7 cm min -1 initialized from [Miller et al., 2015, Sci Transl Med, 7, 314ra183; Miller et al., 2017, Sci Transl Med, 9, eaal0225] et al., 2011, Comp Hepatol, 10, 2; Baratta et al., 2009, Histochem Cell Biol, 131, 713-26] UCKu phagocyte uptake capacity [2.8 ± 1] 10 -9 mg mL -1 initialized from in vitro saturation experiments [Miller et al., 2017, Sci Transl Med, 9, eaal0225]] VTI volume of tumor interstitium 0.105 mL [Schluep et al., 2009, Proc Natl Acad Sci U S A, 106, 11394-9] VTC volume of tumor cells 0.113 mL [Schluep et al., 2009, Proc Natl Acad Sci U S A, 106, 11394-9; Miller et al., 2015, Sci Transl Med, 7, 314ra183] Vtot T total tumor volume 0.3 mL [Schluep et al., 2009, Proc Natl Acad Sci U S A, 106, 11394-9] [Schluep et al., 2009, Proc Natl Acad Sci U S A, 106, 11394-9; Miller et al., 2015, Sci Transl Med, 7, 314ra183] NTAM # TAM 7.5 10 6
[ Miller et al., 2015, Sci Transl Med, 7, 314ra183; Miller et al., 2017, Sci Transl Med, 9, eaal0225] UCTAM TAM uptake capacity [3.5 ± 4] 10 -9 mg mL -1 initialized from in vitro saturation experiments [Miller et al., 2017, Sci Transl Med, 9, eaal0225]] kiTAM 2nd-order TAM uptake 0.08 ± 0.05 (mg/mL) -1 min -1 kpTAM 2nd-order TAM uptake 0.016 ± 0.07 (mg/mL) -1 min -1 kTurn turnover of phagocyte uptake capacity [4.5 ± 1.6] 10 -3 min -1 initialized from in vivo saturation: [Miller et al., 2017, Nat Commun, 8, 15906; Sun et al., 2017, Theranostics, 7, 319-328] y4 : Ku uptake capacity dy4/dt = kTurn (y5 + y5-2 + y5-3) VKu VLV -1 -kKu ( y3-2 y4 + y3 y4 ) y9 : TAM uptake capacity dy9/dt = kTurn ( y10 + y10-2 + y10-3 ) VTAM VTI -1 -kiTAM ( y7 + y7-2 ) y9 -kpTAM ( y1 + y1-2 ) y9 y1-2 : prodrug NP in plasma dy1-2/dt = kq2 / Vp -kel y1-2 + [ PSCP ( y2-2 -y1-2 ) + CLi ( y3-2 -y1-2 ) + PtSt (y7-2 -y1-2) -kpTAM y1-2 y9 VTI ] Vp -1 y2-2 : prodrug NP in intst. heart dy2-2/dt = -PSCP ( y2-2 -y1-2 ) Vh -1 y3-2 : prodrug NP in liver vessel dy3-2/dt = -CLi ( y3-2 -y1-2 ) VLV -1 -kKu y3-2 y4 y5-2 : prodrug NP in Ku cell dy5-2/dt = kKu y3-2 y4 VLV / VKu -kTurn y5-2 -kact y5 y5-2 y6-2 : prodrug NP in Ku sink dy6-2/dt = kTurn y5-2 -kactDC y6 y6-2 y7-2 : prodrug NP in tumor intst dy7-2/dt = PtSt (y1-2 -y7-2) VTI -1 -kTu y7-2 -kiTAM y7-2 y9 y8-2 : prodrug NP in tumor cells dy8-2/dt = kTu y7-2 VTI VTC -1 -kact y8 y8-2 y10-2 : prodrug NP in TAM dy10-2/dt = kiTAM y7-2 y9 VTI VTAM -1 -kTurn y10-2 -kact y10 y10-2 + kpTAM y1-2 y9 VTI VTAM -1 y11-2 : prodrug NP in TAM sink dy11-2/dt = kTurny10-2 -kactDC y11 y11-2 y5-3 : depl. prodrug NP in Ku cell dy5-3/dt = kact y5 y5-2 -kTurn y5-3 y6-3 : depl. prodrug NP in Ku sink dy6-3/dt = kactDC y6 y6-2 + kTurn y5-3 y8-3 : depl. prodrug NP in tu cell dy8-3/dt = kact y8 y8-2 y10-3 : depl. prodrug NP in TAM dy10-3/dt = kact y10 y10-2 -kTurn y10-3 y11-3 : depl. prodrug NP in TAM sink dy11-3/dt = kactDC y11 y11-2 + kTurn y10-3 solvent MMAE n/a n/a + 1 0.04 MMAE-NP n/a n/a n/a n/a n/a ( n M ) *see [Legigan et al., 2012, Angew Chem Int Ed Engl, 51, 11606-10] 
